- Home
- BMEA vs VANI Comparison
BMEA vs VANI Comparison
Compare BMEA & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- VANI
- Stock Information
- Founded
- BMEA 2017
- VANI 1998
- Country
- BMEA United States
- VANI United States
- Employees
- BMEA N/A
- VANI N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- VANI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- BMEA Health Care
- VANI Health Care
- Exchange
- BMEA Nasdaq
- VANI Nasdaq
- Market Cap
- BMEA 65.8M
- VANI 75.2M
- IPO Year
- BMEA 2021
- VANI 2014
- Fundamental
- Price
- BMEA $1.93
- VANI $1.40
- Analyst Decision
- BMEA Strong Buy
- VANI Strong Buy
- Analyst Count
- BMEA 10
- VANI 1
- Target Price
- BMEA $22.30
- VANI $4.00
- AVG Volume (30 Days)
- BMEA 2.3M
- VANI 141.6K
- Earning Date
- BMEA 07-30-2025
- VANI 08-12-2025
- Dividend Yield
- BMEA N/A
- VANI N/A
- EPS Growth
- BMEA N/A
- VANI N/A
- EPS
- BMEA N/A
- VANI N/A
- Revenue
- BMEA N/A
- VANI N/A
- Revenue This Year
- BMEA N/A
- VANI N/A
- Revenue Next Year
- BMEA N/A
- VANI N/A
- P/E Ratio
- BMEA N/A
- VANI N/A
- Revenue Growth
- BMEA N/A
- VANI N/A
- 52 Week Low
- BMEA $1.29
- VANI $0.91
- 52 Week High
- BMEA $13.07
- VANI $1.50
- Technical
- Relative Strength Index (RSI)
- BMEA 50.04
- VANI 74.26
- Support Level
- BMEA $1.58
- VANI $1.26
- Resistance Level
- BMEA $2.03
- VANI $1.30
- Average True Range (ATR)
- BMEA 0.15
- VANI 0.06
- MACD
- BMEA -0.00
- VANI 0.00
- Stochastic Oscillator
- BMEA 80.00
- VANI 69.70
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About VANI Vivani Medical Inc. (DE)
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.